You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The firm is offering an additional 500,000 shares of Class A stock, bringing the total to 4 million shares, offered at $110 per share.
The single-cell and spatial genomics firm is seeking to raise more money from the markets a year after its $410.8 million IPO.
IncellDx is also developing a suite of COVID-19 diagnostic products to answer long-term questions about the treatment of patients still suffering from the disease.
The firm's $42.9 million in total revenues and $.41 loss per share for the second quarter both beat the average analyst estimates.
The firm has partnered with Illumina to use the Dragen Bio-IT informatics platform to help customers analyze data from the new Cancer Transcriptome Atlas panel.
The Seattle firm saw consumables and collaboration revenues fall, however, the GeoMx spatial transcriptomics platform grew instrument revenue.
The Harvard spinout wants its instrumentation and reagent packages to ease the transition for labs interested in high-resolution imaging studies.
The company has developed a microscopy system that allows imaging of a full pathology slide in 21 channels with a single staining process and a rapid turnaround time.
The Pleasanton, California-based firm reported $71.9 million in revenues but missed the consensus Wall Street estimates for quarterly revenues as well as loss per share.
The firm remains on track to ship its first NGS-enabled instruments, along with its new cancer transcriptome atlas panel covering more than 1,800 genes, during Q3.
The World Health Organization will be providing low-cost COVID-19 tests to low- and middle-income nations, according to Reuters.
Nature News examines how the confirmation of Amy Coney Barrett to the US Supreme Court could affect scientific agencies.
Nobel Prize-winner Arthur Ashkin, who developed optical tweezers, has died at 98, the Washington Post reports.
In PNAS this week: altered gene expression in brain samples from Alzheimer's disease patients, effects of gene mutations found in bladder cancer, and more.